Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Linical Co., Ltd. ( (JP:2183) ) just unveiled an update.
Linical Co., Ltd. has revised its consolidated financial forecast for the fiscal year ending March 2025 due to underperformance in new project acquisitions and project delays across Japan, South Korea, Europe, and the United States. Despite the forecasted downturn, Linical has recorded a gain of 107 million yen from income tax adjustments and maintains its dividend forecast, highlighting its commitment to balancing corporate growth and shareholder returns.
More about Linical Co., Ltd.
Linical Co., Ltd. operates within the pharmaceutical and clinical research industry, focusing on providing clinical development solutions. The company serves a global market, including regions such as Japan, South Korea, Europe, and the United States.
Average Trading Volume: 48,225
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen7.86B
See more data about 2183 stock on TipRanks’ Stock Analysis page.